Anal Cancer and Anal Intraepithelial Neoplasia Risk among Patients Treated for HPV-Related Gynecological Diseases-A Systematic Review
- PMID: 37445251
- PMCID: PMC10342585
- DOI: 10.3390/jcm12134216
Anal Cancer and Anal Intraepithelial Neoplasia Risk among Patients Treated for HPV-Related Gynecological Diseases-A Systematic Review
Abstract
Background: The most important causative agent of neoplasms in the anogenital area is the human papillomavirus (HPV). Due to the anatomical proximity of the genital and anus area and the ease with which HPV infection is transmitted, it seems that patients after the treatment of HPV-related gynecological diseases may have an increased risk of developing a second HPV-related neoplasm anal cancer. The aim of this study was to determine the risk of anal intraepithelial neoplasia (AIN) and anal cancer (AC) among patients after the treatment of HPV-related gynecological diseases.
Methods: We conducted a comprehensive review of the available literature from multiple databases. The study was performed following Cochrane Reviewers' Handbook and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2009 guidelines. Moreover, we assessed the quality of each study using QUADAS-2.
Results: Twenty-five studies were included in the final analysis. Patients after the treatment of HPV-related gynecological diseases have a significantly higher risk of AC (mean standardized incidence ratio (SIR) = 5.387, mean incidence risk (IR) = 0.096%, mean IR per 100,000 person-years = 10.37) and AIN (mean IR = 23.683%) compared to the population risk.
Conclusions: patients with HPV-related gynecological diseases should constitute a group for which an appropriate primary and secondary screening for AC should be introduced.
Keywords: HPV; anal cancer; anal intraepithelial neoplasia; cancer; cervix; gynecology; human papillomavirus; intraepithelial neoplasia; vagina; vulva.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.Lancet Infect Dis. 2022 Mar;22(3):413-425. doi: 10.1016/S1473-3099(21)00327-3. Epub 2021 Nov 12. Lancet Infect Dis. 2022. PMID: 34780705 Clinical Trial.
-
A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study.Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2185-2191. doi: 10.1158/1055-9965.EPI-22-0548. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 36126275 Free PMC article.
-
The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: A literature review.J Am Acad Dermatol. 2020 Jan;82(1):202-212. doi: 10.1016/j.jaad.2019.04.067. Epub 2019 May 11. J Am Acad Dermatol. 2020. PMID: 31085272
-
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.N Engl J Med. 2011 Oct 27;365(17):1576-85. doi: 10.1056/NEJMoa1010971. N Engl J Med. 2011. PMID: 22029979 Clinical Trial.
-
Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis.Lancet HIV. 2020 Apr;7(4):e262-e278. doi: 10.1016/S2352-3018(19)30434-5. Epub 2020 Feb 25. Lancet HIV. 2020. PMID: 32109408
Cited by
-
Risk Factors for the Anal and Oral Human Papillomavirus (HPV) Infections among Women with Severe Cervical Lesions: A Prospective Case-Control Study.Biomedicines. 2023 Nov 29;11(12):3183. doi: 10.3390/biomedicines11123183. Biomedicines. 2023. PMID: 38137404 Free PMC article.
-
Anal carcinoma - exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment.World J Exp Med. 2024 Sep 20;14(3):98525. doi: 10.5493/wjem.v14.i3.98525. eCollection 2024 Sep 20. World J Exp Med. 2024. PMID: 39312693 Free PMC article. Review.
References
-
- Silverberg M.J., Lau B., Justice A.C., Engels E., Gill M.J., Goedert J.J., Kirk G.D., D’Souza G., Bosch R.J., Brooks J.T., et al. Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2012;54:1026–1034. doi: 10.1093/cid/cir1012. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Medical